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Abstract 15 
The current gold standard for aneurysm treatment is endovascular coiling. However, recurrence is 16 
observed in over 20% of cases. A novel hydrogel has  been developed to treat aneurysms. This hydrogel 17 
is composed of a polymeric alginate, a novel ion releasing glass and glucono-delta-lactone. This is an 18 
internally setting alginate hydrogel, wherein the setting rate can be controlled by both the glass and the 19 
alginate chemistry. The aim of this work is to examine the effect of each component of the hydrogel and 20 
optimise the composition of the hydrogel, specifically the alginate molecular weight, M/G ratio and 21 
concentration. The effects of gamma sterilisation will also be examined. The results show that alginate 22 
concentration, chemical composition and molecular weight affect the compressive strength, working time, 23 
hardening time and deliverability of the hydrogel. Gamma irradiation of the alginate reduces the 24 
molecular weight, which has a negative effect on the usability of this hydrogel. 25 
 26 
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 1. Introduction 30 
An intracranial aneurysm is an irregular out-pouching of a cerebral artery. It is estimated that 1% to 6% of 31 
the adult population has an intracranial aneurysm (Brisman, Song, & Newell, 2006). A ruptured aneurysm 32 
can lead to stroke, resulting in disability or death. Treatments such as clipping and coiling are currently 33 
used to prevent an aneurysm from rupturing; however, there are a number of problems associated with 34 
these. Clipping the aneurysm involves a craniotomy and carries the risks of infection and scarring 35 
(Brisman et al., 2006). In the United States, the most common treatment method for intracranial 36 
aneurysms is coiling. However, recurrence is common, happening in 20.8% of endovascular coiling cases 37 
(Crobeddu, Lanzino, Kallmes, & Cloft, 2012), indicating that it is a suboptimal treatment method. 38 
In this study we explore the possibility of delivering a hydrogel which will fill the aneurysm more 39 
completely and prevent rupture. This novel hydrogel composite is composed of a polymeric alginate, a 40 
novel ion releasing glass and glucono-delta-lactone (GDL). 41 
Ideally, the hydrogel should adhere to the aneurysm wall preventing migration and aneurysm recurrence. 42 
Additionally, the hydrogel must be able to withstand a compressive stress of at least 22kPa, which relates 43 
to hypertensive blood pressure (Cipolla MJ, 2009). The envisaged hydrogel delivery procedure will 44 
involve inflating a compliant balloon adjacent to the aneurysm neck, as with endovascular coiling. The 45 
novel hydrogel will then be injected through a micro-catheter into the aneurysm whilst the inflated 46 
balloon prevents leakage of the filler into the blood stream (see Figure S 1). To allow for delivery, an 47 
optimum working time of between 10 and 30 minutes has been determined by clinical observation. It has 48 
been determined that the novel hydrogel must be set within 5 minutes of injection (based on the 49 
maximum inflation time for a balloon in the cerebral vasculature. A balloon inflated for greater than 5 50 
minutes may result in cerebral ischemia (Kim Nelson & Levy, 2001). The alginate sterility must also be 51 
considered and this can ordinarily be achieved by moist heat sterilization, gamma-irradiation or ethylene 52 
oxide sterilization (Munarin, Bozzini, Visai, Tanzi, & Petrini, 2013).  53 
Alginate is a polysaccharide composed of β-ᴅ-mannuronic acid (M) and α-ι-guluronic acid (G), giving 54 
alginate an M/G block structure. Alginate has the ability to gel when cross-linked with multivalent ions. 55 
Alginate is typically described in terms of molecular weight and the M/G ratio.  G-rich alginates are 56 
stiffer and more brittle than M-rich alginates (Morais et al., 2013). 57 
The role of the glass in this hydrogel is to deliver a steady release of multivalent ions, controlling the rate 58 
of gelation and the strength of the hydrogel. The more stable the glass the slower the rate of gelation. A 59 
glass that releases a higher quantity of ions will form a stronger hydrogel. Bioactive glasses have also 60 
traditionally been used to deliver therapeutic ions, which encourage cell growth and extracellular matrix 61 
production. This hydrogel formulation could also, in the future, be used to deliver therapeutic ion doses. 62 
 GDL is a lactone that hydrolyses in water to form a gluconic acid, its role in the novel hydrogel is to 63 
acidify the solution. This in turn releases multivalent ions, contained in the glass, allowing them to cross-64 
link with the alginate. The gelation rate of the hydrogel can be tightly controlled by both the composition 65 
of the glass phase and the ratio of constituent components of the gel. An increased amount of GDL results 66 
in increased acidity, causing a more rapid glass ion release and a more rapid gelation.  67 
The aim of this work is to individually vary the concentration of two different alginates, with similar 68 
viscosities but differing molecular weights and M/G ratios and to examine the effect on the mechanical 69 
properties, sample volume conservation, working time, hardening time and deliverability of a hydrogel. 70 
We hypothesise that the strength of the hydrogel will increase with increasing alginate concentration but 71 
the sample size will reduce over time due to the increased cross-linking density. Although alginate is a 72 
Non-Newtonian liquid that undergoes shear thinning, there will likely be a large increase in viscosity with 73 
increasing alginate concentration and this will affect the deliverability of the hydrogel. In addition, the 74 
effect of a reduction in molecular weight by sterilisation on the most suitable alginate is subsequently 75 
examined. Gamma irradiation is known to greatly reduce the molecular weight of alginate and will likely 76 
cause a significant reduction in the hydrogel’s strength. This will also reduce the viscosity which may 77 
help with the deliverability of the hydrogel. Gamma irradiation will be chosen as a possible sterilisation 78 
technique for future work, provided there is a positive outcome of these results. This optimisation is 79 
designed to improve the novel hydrogel’s performance for the treatment of cerebral aneurysms.  80 
2. Material and Methods 81 
 82 
2.1. Materials  83 
 84 
2.1.1. Alginate Purification 85 
All reagents used were purchased from Sigma-Aldrich (Wicklow, Ireland), unless stated otherwise. Two 86 
different techniques were used to produce the two different potassium alginates; a medium viscosity high-87 
G content alginate (MVG) and a medium viscosity high-M content alginate (MVM). The hydrogel was 88 
purified from a sodium salt and alginate to a potassium alginate to reduce the endotoxin levels found in 89 
the supplied alginate (Dusseault et al., 2006). All acid/base solutions were made up in 20 mmol/L of NaCl 90 
in deionised water (DI), unless stated otherwise. 91 
MVG was produced by dissolving 8g of a sodium salt from brown algae in 400 mL of DI. The alginate 92 
pH was raised to 7.0 by adding a 0.5 M potassium hydroxide (KOH). The alginate was then precipitated 93 
by adding 200 mL of methanol per 100 mL of alginate. The alginate was filtered through a 500 µm sieve 94 
after 10 minutes. The alginate was then freeze-dried. 95 
 MVM was produced by dissolving 9 g of sodium alginate was dissolved in 900 mL of 1 mmol/L sodium 96 
EGTA. The solution was then filtered through 11 µm and 2.5 µm filter paper respectively. The alginate 97 
was then precipitated on ice by reducing the pH to 1.5 using a 2 M hydrochloric acid (HCl). The alginate 98 
was decanted through a 500 µm stainless sieve and stirred 30 minutes in 200 mL of a 0.01 M HCl 99 
solution and decanted again. This stirring and decanting was repeated three times. To remove proteins the 100 
alginate was stirred for 30 minutes in 100 mL of a 0.01 M HCl solution with 20 mL of chloroform and 5 101 
mL of 1-butanol, and collected in a 500 µm stainless steel sieve. This washing and collecting was 102 
repeated three times. 350 mL of DI was added and the pH was raised to 7.0 by adding a 0.5 M KOH. The 103 
alginate was stirred in a solution of 20 mL chloroform and 5 mL of 1-butanol per 100 mL of alginate and 104 
centrifuged at a rate of 5,000 rpm for 5 minutes. The alginate was then separated using a pipette from the 105 
chloroform/1-butanol solution. This washing and centrifuging was repeated once. Finally, the alginate 106 
was precipitated by adding 200 mL of ethanol per 100 mL of alginate and filtered after 10 minutes. The 107 
alginate was then freeze-dried.    108 
A sample of the porous freeze-dried solid MVM alginate was gamma irradiated at Synergy Healthcare 109 
(Westport, Ireland) by exposing the sample to a cobalt 60 source until a final irradiation dose of 25kGy 110 
was achieved. 111 
The required amount of freeze-dried alginate, to make the required alginate concentration, was then added 112 
to 12 mL of DI.     113 
2.1.2. Glass 114 
The glass had a mole fraction composition of 0.33SiO2•0.18Ga2O3•0.23CaO•0.11P2O5•0.15CaCl2. A glass 115 
frit of this composition was produced by melting the appropriate raw materials in a platinum 10% 116 
rhodium crucible at 1480 °C for 1 hour. The molten mixture was then shock quenched into water. A glass 117 
powder was then produced by grinding 30 g of glass frit using 15 mm diameter zirconia balls in a ball 118 
mill (Pulverisette 6 classic Mono planetary ball mill, Fritsch GmbH, Germany) at 500 rpm for 10 119 
minutes. Particles over 500 µm were removed by sieving the glass powder through a 500 µm sieve. 7.5 g 120 
of the <500 µm particles were ground in 22.5 mL of DI using 5 mm zirconia balls in a ball mill at 500 121 
rpm for 10 minutes. The glass mixture was dried in the oven at 130 ºC. 122 
2.1.3. Glucono-Delta-Lactone 123 
D-(+)-Gluconic acid δ-lactone was purchased from Sigma Aldrich. The GDL particle size was reduced by 124 
grinding 30 g at 500 rpm for 5 minutes using a ball mill. Particle size analysis is shown in Figure S 2. 125 
2.1.4. Hydrogel preparation 126 
The required amount of freeze-dried alginate was dissolved in 1.2 mL of DI. The novel hydrogel was 127 
produced by mixing 4.6% of glass powder, 50 mg of GDL with the 1.2 mL of the alginate solution for 1 128 
 minute, unless otherwise stated. Design Expert 9 (Stat-Ease, Minneapolis, USA) was used to determine 129 
the four alginate concentrations to be tested; 0.5%, 2.5%, 4.5% and 6.0%.  130 
2.2. Methods 131 
 132 
2.2.1. Alginate Characterisation 133 
Gel permeation chromatography (GPC) and nuclear magnetic resonance spectroscopy (1H NMR) were 134 
carried out as follows in order to characterise the alginates produced. 135 
GPC was carried out using a liquid chromatography system (Agilent 1200, Agilent, USA) equipped with 136 
a Suprema Linear GPC column (PSS, Germany). The mobile phase used consisted of 0.1 M disodium 137 
hydrogen phosphate containing 0.5 g/L of sodium nitrate buffered to pH 9. All samples were injected at a 138 
concentration of 1 mg/mL, at a flow rate of 0.5 mL/min. Pullulan standards were used to construct the 139 
calibration curves as alginate standards are not available. This is not an ideal standard as it can 140 
overestimate the molecular weight (Andersen, Strand, Formo, Alsberg, & Christensen, 2012). However, 141 
they are commonly used in determining molecular weights of alginates with a refractive index detector 142 
(Barbetta, Barigelli, & Dentini, 2009)(Ding, Zhou, Zeng, Wang, & Shi, 2017)(Aida, Yamagata, 143 
Watanabe, & Smith, 2010).  144 
1H NMR analysis of the potassium alginate was carried out using a modified version of the standard 145 
ASTM F2259–03. The alginate solution was prepared by mixing the alginate to a 0.1% (w/v) in DI. HCl 146 
was used to bring the alginate pH to 5.6 and the alginate solution was stored in a water bath at 100 °C for 147 
1 hour. HCl was used to further adjust the pH of the alginate to 3.8. The solution was stored again in a 148 
water bath at 100°C for 30 minutes. The pH was then raised to 7 using NaOH and the alginate was freeze 149 
dried. The alginate was then dissolved in 5 mL of 99% D2O and freeze dried overnight.  12 mg of alginate 150 
was dissolved in 1 mL of D2O and placed in a NMR tube. The NMR of the alginate was tested using a 151 
Bruker Advance 400 (Bruker, Massachusetts, USA) at 80°C. 64 scans were carried out using a 2s 152 
relaxation delay. The M-block, G-block and alternating block sequences content were then calculated as 153 
per the equations in ASTM F2259-03 using the produced spectrum. 154 
 155 
2.2.2. Viscosity 156 
The viscosity of each alginate at varying concentrations was determined at 24ºC using a SV-10 tuning 157 
forks Vibro Viscometer (A&D Company, Japan) running a sine wave formation at a constant frequency 158 
of 30Hz and amplitude of less than 1 mm. The viscometer measures up to 10,000 mPa.s. 159 
2.2.3. Volume Conservation 160 
To examine whether the 1.2 mL hydrogel volume was conserved over time, the samples volumes were 161 
measured after storage in 20 mL of DI for 1, 3 and 7 days. The hydrogel was mixed and poured into a 162 
 cylindrical mould (10 mm diameter and 14 mm height). The hydrogel was left to set for 1 hour and 163 
incubated in DI at 37°C for the required amount of time. After the required time the hydrogel was 164 
removed from the DI and dimensions were measured using callipers. ‘Volume conservation’ was 165 
calculated by calculating the change in volume compared to the original (pre-incubated) volume. 166 
2.2.4. Compression testing 167 
To examine the mechanical properties of the novel hydrogel, compression testing was carried after storing 168 
the novel hydrogel for 7 days in DI. The compression testing samples were made as described above. 169 
After the required amount of time the hydrogel sample was compressed using a mechanical testing 170 
machine (Z005, Zwick Roell, Germany) equipped with a 5 kN load cell. A 0.005 N pre-load was applied. 171 
The samples were compressed up to 70% strain at a crosshead speed of 2 mm/min. 172 
2.2.5. Working and Hardening Time 173 
The working and setting time of each alginate was determined using a modified version of ISO 9917. The 174 
setting time was found by mixing the hydrogel and placing a circular indenter (diameter: 6 mm, weight: 175 
20 g) on the sample every 60 seconds. The hydrogel was considered set when it held the indenter without 176 
causing an indentation in the hydrogel. 177 
The working time was determined by stirring the hydrogel every 1 minute until the hydrogel would not 178 
return to its original shape. 179 
The hardening time is defined as the difference between the setting time and working time of the 180 
hydrogel. 181 
2.2.6. Deliverability 182 
The deliverability of each alginate was tested by injecting the hydrogel by hand at the varying alginate 183 
concentrations through a 3F micro catheter, using a quick stop syringe. 184 
The optimum hydrogel was then injected through a 2.7F micro-catheter into a silicone side wall 185 
aneurysm, (neck size of 2.5 x 6 mm, model H+N-S-A-005, Elastrat, Switzerland). A pulsatile blood pump 186 
(1423, Harvard Apparatus, Mass., USA) was used to pump a 36:64 water:glycerol solution through the 187 
aneurysm and to provide physiologically correct blood pressure (140/80 mmHg) and flow rates (700 mL 188 
l/min). The pressure was measured at the aneurysm inlet and outlet using pressure transducers (DTX Plus 189 
Disposable Pressure Transducer, Argon) which was amplified using a bridge analogue input (NI9237, 190 
National Instrument) and the pressure was monitored using LabView. A 5 mm diameter balloon (Trek, 191 
Abbott) was inflated adjacent to the aneurysm neck, to facilitate placement. 192 
2.2.7. Statistical analysis 193 
 Student T-tests (p<0.05) and ANOVA with Bonferroni’s post hoc test was carried out using IBM SPSS 194 
(IBM, Armonk, NY). 195 
3. Results 196 
 197 
3.1.Effect of alginate molecular weight and chemical composition 198 
 199 
3.1.1. Alginate Characterisation 200 
GPC was carried out to determine the molecular weight (MW) of each alginate and 1H NMR spectra of 201 
the alginates were used to determine the guluronic acid (FG), mannuronic acid (FM) and alternating block 202 
(FGM) fractions, which were calculated as per ASTM F2259 – 03. 203 
Table 1 gives the calculated results of the alginates produced; see Figure S 3 and Figure S 4 for graphs. 204 
MVG produced a low molecular weight (60kDa) alginate with a high-G content. MVM produced a high 205 
molecular weight (700kDa) alginate with a high-M content. 206 
Table 1 Alginate chemical composition 207 
Sample Molecular 
weight 
FG FM M/G FGG FMM FGM ?̅?𝐆>𝟏 
MVG 60kDa 0.52 0.48 0.92 0.38 0.33 0.14 7.08 
MVM 700kDa 0.37 0.63 1.7 0.18 0.45 0.18 3.59 
 208 
3.1.2. Volume Conservation 209 
The volume of the samples with a low alginate concentration reduced in size, see Figure 1. A 4.5% 210 
alginate concentration approximately maintains its size or slightly expands (<5%) whilst the samples at 211 
the 6.0% alginate concentration expanded after 7 days. 212 
 213 
Figure 1 Volume conservation after storage for 7 days in DI at 37°C (n=5) 214 
3.1.3. Viscosity 215 
Both alginates have a similar viscosity at each concentration and the viscosity increases with increasing 216 
alginate concentration (Figure S 5). Both the alginates have viscosity greater than 10,000 mPa.s at the 217 
6.0% alginate concentration.  218 
 3.1.4. Compression testing 219 
Both hydrogel compositions at each concentration far exceed the minimum compressive strength (22 kPa) 220 
required.  221 
 222 
Figure 2 (a) Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain) of the alginates at the 4 223 
concentrations after storage for 7 days in DI at 37°C 224 
The strength of the hydrogel was observed to increase from 0.5% to 2.5% alginate concentration. This 225 
was expected to continue with increased alginate concentration, as observed elsewhere (Draget, Skjåk 226 
Bræk, & Smidsrød, 1994; C K Kuo & Ma, 2001; Becker, Kipke, & Brandon, 2001), however, this is not 227 
observed here. The decreased strength observed at 4.5% and 6.0% may be caused by shortage of cross-228 
linking cations. As there is no increase in GDL or glass content there will be no increase in ion 229 
availability to cross-link with increasing number of chains provided by the increased alginate 230 
concentration.  231 
Figure 3 shows that increasing the glass content increases the modulus and strength of the hydrogel at a 232 
4.5% alginate concentration. Increasing the glass content from 4.6% to 9.2% more than doubles both the 233 
strength and modulus of the hydrogel, with no further increase being observed with further glass addition 234 
(13.8%). This may be increased further with an increase in GDL content.  235 
 236 
Figure 3 (a)Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain)  of 4.5% and 6.0% MVM 237 
alginate with 50 mg GDL and an increased glass content after storage for 1 day in DI at 37°C (n=5) 238 
3.1.5. Working Time and Hardening Time  239 
 Figure 4 shows the working and hardening time of each composition. For both alginates only the 4.5% 240 
and 6.0% alginate concentrations are within the required working and hardening time. There is an 241 
approximately linear decrease in working time for the MVG and MVM alginate (R2 = 0.91 and R2 = 0.94, 242 
respectively) and hardening time for the MVM alginate (R2 = 0.93) with increasing alginate 243 
concentration. As there is no significant difference between the 0.5% and 2.5% hardening time (p < 0.05), 244 
there is not a linear reduction for the MVG alginate. 245 
 246 
Figure 4 Alginate a) working and b) hardening time (n=5) 247 
3.1.6. Deliverability 248 
The alginate concentration of 0.5% (either MVG or MVM) gave insufficient viscosity (41-44mPas) to 249 
remain in the aneurysm when blood flow was applied. The 2.5% and 4.5% alginate concentration of both 250 
MVG and MVM alginates (<10,000 mPa.s) would inject through the micro-catheter easily, up to 20 251 
minutes after mixing. The MVG and MVM alginates at 6.0% alginate concentration (>10,000 mPa.s) 252 
would not inject through the micro-catheter, blocking it 2 minutes after mixing the hydrogel. 253 
As the 4.5% concentration of the MVM alginate had the correct strength, sufficient volume conservation, 254 
and correct working and hardening times it was selected to inject into the aneurysm model. With the 255 
balloon inflated and the flow pump on, the hydrogel was injected into the 10 mm aneurysm with a 256 
2.5x2.5 mm neck two minutes before the end of the working time (22 minutes after mixing). The 257 
hydrogel was fully injected by the working time and the balloon remained inflated for two minutes. The 258 
hydrogel stayed within the aneurysm and remained in the aneurysm with no perceptible erosion once the 259 
balloon was deflated for the time tested (30 minutes). 260 
3.2. Effect of Gamma Irradiation 261 
As previously stated, the MVM alginate was the more suitable of the two alginates examined for 262 
treatment of cerebral aneurysms and hence was selected for gamma irradiation. A sample of the alginate 263 
 was gamma irradiated by Synergy Healthcare (Westport, Ireland) at 25kGy to examine the effects of a 264 
change in molecular weight alone and for sterilisation purposes. 265 
3.2.1. Alginate Characterisation 266 
GPC and 1H NMR showed that gamma irradiation causes a reduction in alginate molecular weight to 267 
180kDa without a change to the alginate chemical composition (Table 1).   268 
3.2.2. Volume Conservation 269 
Figure 5 shows that, again, the lower irradiated alginate concentrations shrink in volume whilst the 6.0% 270 
alginate concentration increases in volume over 7 days for both alginates. The 4.5% alginate 271 
concentration has minimal expansion in volume. 272 
 273 
Figure 5 Volume conservation after storage for 7 days in DI at 37°C (n=5) 274 
3.2.3. Viscosity 275 
The results show that gamma irradiation reduces alginate viscosity, with values ranging from 2.83 to 276 
86.43 mPa.s. The viscosity increases by approximately 6.25 mPa.s for each 1% increase in alginate 277 
concentration for the gamma irradiated alginate, see Figure S 8. 278 
 279 
3.2.4. Compression testing 280 
Reduction in molecular weight caused by gamma irradiation greatly affects the compressive stress and 281 
incremental modulus of the hydrogel compared to the non-irradiated sample (p > 0.05). Although the 282 
gamma irradiated alginate has a compressive strength that exceeds the limit discussed in the introduction 283 
(22 kPa), the incremental modulus of the alginate decreases with increasing alginate concentration and at 284 
each concentration has a decreased strength compared to the non-irradiated alginate, see Figure 6.  285 
  286 
Figure 6 (a) Compressive stress up to 70% strain and (b) Incremental modulus (30 to 50% strain) of irradiated and non-287 
irradiated alginate compositions after storage for 7 days in DI at 37°C 288 
3.2.5. Working Time and Hardening Time  289 
The reduction in molecular weight of the gamma irradiated alginate significantly increases the working 290 
and hardening time (p > 0.05), see Figure 9. The working and hardening times decrease linearly with 291 
increasing alginate concentration for both irradiated and non-irradiated samples, i.e. R2 = 0.91, 0.91 and 292 
R2 = 0.91, 0.92, respectively. However, at each concentration test, the gamma irradiated alginate is not 293 
within the time limits for its intended application. 294 
 295 
 296 
Figure 7 Hydrogel a) working and b) hardening time (n=5) 297 
3.2.6. Deliverability 298 
None of the gamma irradiated alginate concentrations had sufficient viscosity to remain in the aneurysm 299 
when blood flow was applied, similar to that of the 0.5% alginate concentration of the non-irradiated 300 
alginate.   301 
4. Discussion  302 
From the GPC and 1H NMR results we can see that two different alginates were produced, a MVM with a 303 
high molecular weight and a MVG with a low molecular weight.  Though the molecular weight of the 304 
 MVG alginate is over ten times less than that of the MVM alginate, the viscosities are similar (Figure S 305 
5). This is not typical but may be due to differences in M/G ratios and G-block length, with higher G 306 
content and length alginates being typically stiffer and more viscous compared to alginates with a high-M 307 
content (Smith & Miri, 2011)(Nedovic & Willaert, 2013)(Jothisaraswathi & Rengasamy, 2006)(Schmid, 308 
Fariña, Rehm, & Sieber, 2016). It has been shown that varying the alginate purification method results in 309 
alginates with significantly different viscosities. The varying alginates and purification methods used here 310 
may have an additional effect on the viscosity of the alginate due variances in residual salts and impurities 311 
and the resulting pH of the alginate solution (Dusseault et al., 2006; K. Y. Lee & Mooney, 2012; 312 
McHugh, 2003).  313 
It is clear from the results that the cross linking density of the hydrogel is important to control the strength 314 
and volume conservation. At the 0.5% alginate concentration there is likely a shortage of alginate chains 315 
and an excess of cations. At a 4.5% and 6.0% alginate concentration there is a shortage of cross-linking 316 
ions and, as a result, there are alginate chains that are not optimally cross-linked. 317 
The sample volume conservation exhibits results similar to those described by Kuo et al (Catherine K 318 
Kuo & Ma, 2008). At a 0.5% and 2.5% alginate concentration the samples shrink and the 4.5% and 6.0% 319 
alginate concentration samples expand (Figure 1). This may be due to the hydrogel’s cross-linking 320 
density decreasing with increasing alginate concentration as a result of the glass content, and hence ion 321 
content, remaining constant. The lower concentration alginates have an increased cross-linking density. 322 
This increased cross-linking increases the elastic forces that can resist the swelling caused by water 323 
molecules diffusing into the hydrogel. As the concentration increases the cross-linking density decreases 324 
allowing water to diffuse through the hydrogel and swell. Neither significant shrinkage nor expansion is 325 
desired, as shrinkage may contribute to aneurysm recurrence and excessive sample expansion may cause 326 
aneurysm rupture. Samples produced from 4.5% alginate concentration exhibit minimal swelling, which 327 
suggests that this alginate concentration provides a cross-linking density that provides a high strength 328 
while conserving sample volume. 329 
For both the MVG and MVM alginate the incremental modulus and compressive strength increase from 330 
0.5% to 2.5% alginate concentration (Figure 2). The incremental modulus and compressive strength then 331 
decreases with further increased alginate concentration (≥2.5%). The decrease above 2.5% alginate was 332 
unexpected and may be due to a shortage of cross-linking ions. This shortage of ions may reduce the 333 
cross-linking density and result in an inhomogeneous hydrogel that is prone to fracture. To explore this 334 
further, the glass content was increased. This increased the strength for the 4.5% and 6.0% alginate 335 
concentration whereby the increase in cations provided a higher cross-linking density (Figure 3). For each 336 
of the concentrations, the MVM alginate had the highest modulus and compressive strength for each 337 
 alginate concentration. Typically, the high-G alginate would have the higher strength (Draget et al., 338 
1994); however, the increased molecular weight of the MVM alginate may compensate for the lower G-339 
block content and provides increased entanglements. 340 
Though the MVG alginate has the shortest working time, the MVM alginate has the shortest hardening 341 
time at each alginate concentration (Figure 4). This indicates that the working time is governed mostly by 342 
the chemical composition of the alginate with a high-G content providing a decreased working time. The 343 
hardening time of the alginate is governed mainly by the molecular weight of the alginate with a high 344 
molecular weight alginate having decreased hardening time. Increasing the alginate concentration of each 345 
alginate provides an increased number of ionic cross-linking locations and increased likelihood of chain 346 
entanglements, causing working and hardening time to reduce in each hydrogel.  347 
The deliverability of the hydrogel can be determined from the viscosity, with ungelled alginates up to 348 
9,000 mPa.s being injectable through a micro-catheter. For the intended applications of this hydrogel; the 349 
strength, conservation of sample volume, working time and hardening time, along with the deliverability 350 
of this hydrogel must be considered. The 4.5% concentration of the MVM alginate met each of the 351 
requirements and was tested in an aneurysm model with physiological pressures. This hydrogel remained 352 
in the aneurysm without migrating. 353 
Gamma irradiation of the MVM alginate was shown to have no effect on the M/G ratio of the alginate. 354 
However, it does cause scissions of the glycosidic bonds, which reduces the molecular weight of the 355 
alginate.  356 
As expected, viscosity was seen to decrease with gamma irradiation of the MVM alginate, as expected, 357 
due to decreased chain entanglements (C K Kuo & Ma, 2001; Dusseault et al., 2006; Rendevski & 358 
Mahmudi, 2012; Ouwerx, Velings, Mestdagh, & Axelos, 1998)  359 
From the alginate working and hardening time data it can be seen that the gamma irradiated alginate has 360 
the longest working and hardening time due to the high-M content and low molecular weight having a 361 
reduced number of ionic cross-linking locations (Popeski-Dimovski et al., 2012). Although usability of 362 
the gamma irradiated alginate may be improved by increasing alginate concentration and optimising the 363 
glass and GDL content, an alternative method of sterilization may be more efficient, such as sterilisation 364 
by filtration in a sterile manufacturing environment. 365 
A range of injectable polymer formulations have been developed for soft tissue applications but many 366 
contain toxic monomers, activators and free radicals. The gelation rate of the hydrogel described here is 367 
 slow compared to other alginate hydrogels (Larsen, Bjørnstad, Pettersen, Tønnesen, & Melvik, 2015; Lee 368 
et al., 2003), which allows the hydrogel to be delivered and set, within a clinically applicable time. 369 
Though GDL can be used with alginate to produce acid gels, this is likely not the case with the current 370 
hydrogel due to the high strengths and relatively rapid gelation rates observed. The addition of GDL 371 
results in a reduced pH during setting, which may affect the hydrogel’s biocompatibility. The pH of the 372 
storage medium drops by 0.50 with the 4.5% high-M alginate. However, the presence of alkali ions in the 373 
bioactive glass has a neutralizing effect over 24 hours. It should be noted that this temporary reduction in 374 
pH, as occurs with many synthetic biomaterials, may result in an increased inflammatory and fibrotic 375 
response in vivo (Edgar et al., 2016).  376 
For an aneurysm filler to be effective it should have sufficient strength in order to behave similarly to 377 
native cerebral tissue; diverting flow and withstanding haemodynamic stresses caused by arterial 378 
expansion and contraction and blood flow forces (static, dynamic and shear). A low elastic modulus is 379 
required to insure stress caused by blood flow is not transferred to the damaged tissue, causing aneurysm 380 
rupture. A calcium alginate gel that was designed for embolization was reported to have a compressive 381 
strength of 124kPa at 60% strain (Becker et al., 2001). Onyx®, is a non-adhesive material approved for 382 
the treatment of cerebral aneurysms in Europe, has been observed to have a maximum compressive 383 
strength of 3 MPa (Ohyama, Ko, Miura, Iwata, & Taki, 2004). However, Onyx® sets rapidly when in 384 
contact with blood, which combined with the slow injection rate, is not ideal for placement.  385 
The optimised hydrogel in this study exhibits a compressive strength of 280 kPa. Although it is not equal 386 
in strength to Onyx®, it may act to support the existing tissue in its function, without transferring 387 
excessive stress to the damaged tissue. The optimised hydrogel reported herein has higher incremental 388 
modulus and compressive strength compared to those of other ionically cross-linked alginate hydrogels 389 
described in the literature at similar alginate concentrations and chemical compositions (Becker et al., 390 
2001; C K Kuo & Ma, 2001). This novel material reported herein likely has a greater mechanical integrity 391 
than the currently used coil technology that can compact with blood flow, which though not optimal, 392 
continues to function in this mechanical environment (Gallas et al., 2009; Sluzewski et al., 2004). 393 
Agglomerates were clearly visible in the hydrogel both during and after setting, which may affect 394 
consistency of strength and setting, therefore, future testing will be carried out to minimise these 395 
agglomerates. The adhesive nature of the hydrogel will also be examined as this is important to reduce 396 
aneurysm recurrence. Further optimisation of the sterilisation techniques for each hydrogel component of 397 
the hydrogel will also need prior to commercial application. 398 
5. Conclusion 399 
 From the results it can be seen that alginate concentration, molecular weight and chemical composition 400 
affect the sample volume conservation, viscosity, strength, deliverability, working and hardening time of 401 
the novel hydrogels. An alginate with an increased molecular weight and high-M content provides a 402 
hydrogel with an increased working time and decreased hardening time while providing the required 403 
strength which is advantageous for a cerebral aneurysm filler. Alginates with a viscosity between 2,000 404 
mPa.s and 9,000 mPa.s can be injected through a micro catheter while providing sufficient viscosity to 405 
remain within an aneurysm without migration. 406 
Sterilisation by gamma irradiation causes a reduction of molecular weight which decreases the alginate’s 407 
viscosity and strength and increases the hydrogel’s working and hardening time. This is undesirable for 408 
the treatment of cerebral aneurysms. For this application, an alternative, less aggressive method of 409 
sterilisation will be required. 410 
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Figure S 6 1H NMR of gamma irradiated and non-irradiated alginate 520 
The GPC, Figure S 7, shows that gamma irradiation causes scissions of the glycosidic bonds, reducing the 521 
molecular weight of the alginate.  522 
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Figure S 7 GPC of gamma irradiated and non-irradiated alginate 525 
Using Equation S1 it was calculated that gamma irradiation causes approximately 3.3 chain breaks per 526 
molecule.  527 
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𝑁 =
𝑀𝑜
𝑀
− 1 529 
Equation S 1 Calculating chain breaks per molecule 530 
   Where Mo is the original molecular weight and M is the molecular weight of the alginate following 531 
irradiation (D. W. Lee et al., 2003). 532 
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